Related by context. All words. (Click for frequent words.) 71 clinically relevant 67 statistically significant 64 clinically meaningful improvement 64 teriflunomide 63 statistical significance 63 tocilizumab 62 ataluren 62 clinically meaningful improvements 62 achieved statistical significance 62 pharmacodynamic 62 antipsychotic efficacy 62 glucose lowering 61 primary endpoint 61 favorable pharmacokinetic profile 61 viral kinetics 61 LEVADEX 61 alteplase 61 complete cytogenetic response 61 tipranavir 61 cardiovascular morbidity 61 tapentadol ER 60 apremilast 60 anti leukemic 60 desvenlafaxine succinate 60 abatacept 60 ticagrelor 60 NLX P# 60 demonstrated clinically meaningful 60 neurologic progression 60 statistically significant reduction 60 insulin glargine 60 mg dose 60 β blockers 60 secondary efficacy endpoints 60 fondaparinux 60 secondary endpoint 60 insulin detemir 60 paricalcitol 60 noninferiority 60 virologic 60 mucosal healing 60 ruboxistaurin 60 tiotropium 60 hour bronchodilation 60 riociguat 59 adalimumab 59 rotigotine 59 primary efficacy endpoints 59 pramlintide 59 NIHSS 59 monotherapy 59 decitabine 59 Crohn Disease Activity 59 tumor shrinkage 59 tolerability 59 pramipexole 59 efficacy endpoints 59 surrogate endpoint 59 insulin degludec 59 bronchodilation 59 PASI scores 59 dose proportionality 59 primary efficacy endpoint 59 statistically significant p = 59 vandetanib 59 pharmacologic 59 sustained virologic response 59 LDL lowering 59 lacosamide 59 CINQUIL 59 TRIOLEX 59 platelet reactivity 59 achieved ACR# 59 CIMZIA TM 59 serum phosphate 59 canakinumab 59 virologic response 58 pregabalin 58 LEXIVA r 58 APTIVUS r 58 GAMMAGARD 58 viral kinetic 58 recurrent glioblastoma multiforme 58 lumbar spine BMD 58 dasatinib 58 statistically significant improvement 58 ADAS Cog 58 secondary endpoints 58 platelet inhibition 58 ZOMIG Nasal Spray 58 QTc 58 surrogate markers 58 bendamustine 58 CCyR 58 ZOLINZA 58 etanercept 58 BENICAR HCT 58 ACZ# 58 angiographic outcomes 58 sipuleucel T 58 efficacy endpoint 58 ibandronate 58 pCR 58 INCB# [001] 58 extrapyramidal symptoms 58 hemoglobin A1c levels 58 primary endpoints 58 diabetic neuropathic pain 58 Subgroup analyzes 58 pertuzumab 58 pharmacodynamic PD 58 Solid Tumors criteria 58 glycated hemoglobin levels 58 macrovascular 58 analgesic efficacy 58 glycosylated hemoglobin HbA1c 58 PNH patients 58 virological response 58 #mg BID [001] 58 tolerability profile 58 evaluable 58 Virulizin ® 58 dose limiting toxicities 58 tipranavir r 58 sustained virological response 58 ACTEMRA 57 Instanyl 57 clinically meaningful efficacy 57 bosentan 57 clinically meaningful reductions 57 testosterone supplementation 57 glatiramer acetate 57 oral rivaroxaban 57 clinically meaningful differences 57 biologic plausibility 57 ULORIC 57 CIMZIA ™ 57 Campath alemtuzumab 57 clinical endpoints 57 prespecified 57 paliperidone ER 57 cardioprotective effects 57 pomalidomide 57 placebo controlled clinical trials 57 PRT# 57 oral FTY# 57 octreotide 57 S/GSK# 57 ramelteon 57 ALGRX 57 pyridostigmine 57 brivaracetam 57 Amigal 57 mg doses 57 complete remissions 57 placebo controlled clinical 57 demonstrated statistically significant 57 pharmacokinetic PK profile 57 HbA1c levels 57 PYY 57 FOLFIRINOX 57 androgen deprivation 57 mg kg dose 57 neuroregenerative 57 lipid profiles 57 GnRH agonists 57 Tyrima 57 antiangiogenic therapy 57 antioxidant supplementation 57 relapsing MS 57 tezampanel 57 dose Iluvien 57 A1c levels 57 complete cytogenetic 57 ATACAND 57 PSADT 57 AEGR 57 DAPT 57 infliximab 57 symptomatic VTE 57 adenoma recurrence 57 #mg dose [001] 57 methotrexate monotherapy 57 posaconazole 57 Psoriasis Area 57 #mg/day [001] 57 statistically significant differences 57 antihypertensive therapy 57 renal toxicity 57 safinamide 57 sUA 57 interferon alfa 2b 57 iniparib 57 antitumour activity 57 NPH insulin 57 Ophena TM 57 nab paclitaxel 57 adrenal suppression 57 selenium supplementation 57 prognostic indicators 57 AZILECT 57 symptom severity 57 caspofungin 57 RoACTEMRA 57 teriparatide 57 somatostatin analog 57 elagolix 57 mg QD 56 azacitidine 56 composite endpoint 56 MAGE A3 ASCI 56 Elocalcitol 56 opioid analgesia 56 simvastatin ezetimibe 56 morphometric vertebral fractures 56 virological suppression 56 prospectively defined 56 fosbretabulin 56 maximal dose 56 DMARD 56 #.#/#.# mmHg [001] 56 rt PA 56 lipid lowering therapy 56 corrected QT interval 56 adjuvant therapy 56 seropositive patients 56 urate lowering therapy 56 liver histology 56 cabazitaxel 56 relapsed SCLC 56 Kaplan Meier analysis 56 antidepressant efficacy 56 nonsignificant 56 antiarrhythmic 56 pharmacokinetic profile 56 GSK# [001] 56 #mg dose [002] 56 carotid IMT 56 BENICAR 56 tolvaptan 56 guanfacine extended release 56 imatinib therapy 56 aripiprazole 56 Hb A1C 56 oral anticoagulation 56 velafermin 56 PXD# 56 cinacalcet 56 preclinically 56 heavily pretreated 56 active comparator 56 ACR# response 56 abiraterone acetate 56 fluvastatin 56 undetectable HCV RNA 56 TOLAMBA 56 CIMZIA TM certolizumab pegol 56 certolizumab pegol 56 NATRECOR R 56 peg interferon 56 AGILECT ® 56 metreleptin 56 prespecified secondary 56 KRN# 56 radiographic progression 56 serum uric acid 56 randomized trials 56 peginterferon 56 QNEXA 56 Phase 2a trial 56 tanespimycin 56 tolerability profiles 56 varespladib 56 alvimopan 56 ACR# [002] 56 serum phosphorus 56 antitumor activity 56 serum urate 56 randomized clinical trials 56 ADAS cog 56 calcitriol 56 creatine supplementation 56 certolizumab 56 mcg dose 56 interferon beta therapy 56 erlotinib Tarceva 56 briakinumab 56 Primary endpoints 56 PREZISTA r 56 pramlintide metreleptin combination 56 aromatase inhibitor therapy 56 viral suppression 56 statistically significant efficacy 56 subcutaneous insulin 56 ProSavin 56 disease progression 56 non inferiority 56 aldosterone antagonists 56 6MWD 56 fasting plasma glucose 56 blood Phe 56 glycemic variability 56 Secondary endpoints 56 pimecrolimus cream 56 Protelos 56 PROMACTA 56 HuMax EGFr 56 GnRH agonist 56 MERLIN TIMI 56 dose colchicine 56 Doxil ® 56 MCyR 56 anti androgen 56 diabetic gastroparesis 56 YMRS 56 secretin 56 fructosamine 56 pegylated interferon alfa 2b 56 EDSS 56 HbA1c 56 CLARITY study 56 LATUDA 56 rhIGF 56 vidofludimus 56 pharmacokinetic PK 56 thromboembolic events 56 rHuPH# 56 mg BID 56 plus methotrexate 56 APPRAISE 56 pharmacokinetic 56 baminercept 56 lispro 55 systemically administered 55 Symadex 55 HIV RNA 55 MGd 55 HBeAg seroconversion 55 oral Xeloda 55 liraglutide 55 CLA supplementation 55 Capesaris 55 chemoradiotherapy 55 uric acid lowering 55 ADCS CGIC 55 colesevelam HCl 55 NATRECOR ® 55 Onrigin 55 neurocognitive function 55 mycophenolate mofetil 55 reach statistical significance 55 glargine 55 oral diclofenac 55 ARB telmisartan 55 sunitinib 55 glycemic control 55 enoximone 55 inflammatory lesions 55 strontium ranelate 55 triamcinolone 55 tesofensine 55 GFT# 55 CANCIDAS 55 lipid lowering 55 dose escalation 55 ALA PDT 55 Pharmacokinetic 55 placebo 55 paclitaxel eluting stents 55 mealtime insulin 55 FOLPI 55 mTOR inhibitors 55 secondary efficacy endpoint 55 clodronate 55 LVEF 55 zonisamide SR 55 recurrent GBM 55 #mg/day [002] 55 tecarfarin 55 COPAXONE R 55 dyslipidaemia 55 nephrotoxicity 55 PEGylated interferon beta 1a 55 Durezol 55 BoNTA 55 Potiga 55 APOPTONE 55 obatoclax 55 RE LY ® 55 Scale EDSS 55 knee osteoarthritis OA 55 Azixa 55 tumor histology 55 antitumor effect 55 pharmacokinetic characteristics 55 pharmacodynamic effects 55 asymptomatic carotid stenosis 55 HORIZONS AMI trial 55 HbA 1c 55 serum phosphorous 55 cediranib 55 belimumab 55 osteopenic 55 olmesartan 55 TriRima 55 sitagliptin 55 octreotide LAR 55 chlorambucil 55 plasma renin activity 55 avosentan 55 ACTEMRA TM 55 anakinra 55 rosuvastatin #mg 55 atherosclerosis regression 55 MADRS score 55 maximally tolerated dose 55 seroprotection 55 durable remissions 55 ischemic cardiovascular 55 placebo controlled trials 55 insulin analogs 55 microvascular complications 55 fulvestrant 55 IRESSA 55 imetelstat 55 Ilaris 55 hypogonadal men 55 TNF inhibitor 55 statin therapy 55 pharmacological interventions 55 infarct size 55 lipid parameters 55 selective modulator 55 favorable tolerability 55 bicifadine 55 ancrod 55 INCB# [002] 55 PSN# [002] 55 dosage regimens 55 placebo p = 55 headache nasopharyngitis 55 antithrombotic 55 INVEGA ® 55 free survival PFS 55 patients evaluable 55 DCCR 55 rtPA 55 vasomotor symptoms 55 rFVIIa 55 macrovascular disease 55 vildagliptin 55 PROCHYMAL 55 atorvastatin #mg 55 Preclinical studies 55 SERCA2a 55 basal bolus regimen 55 Torisel 55 retinal thickness 55 doxorubicin docetaxel 55 evaluating REVLIMID 55 clinically 55 Combination therapy 55 FFNS 55 QTcF 55 Epanova 55 thiazolidinedione 55 GOUT 55 DAVANAT 55 rosuvastatin 55 Aptivus ® 55 bortezomib 55 levosimendan 55 HGS ETR1 55 QTc intervals 55 intravenous cyclophosphamide 55 nilotinib 55 rapid virologic response 55 IRX 2 55 IOP lowering 55 thromboembolic 55 oxycodone CR 55 WOMAC pain 55 serum urate levels 55 SCIg 55 insulin lispro 55 intermittent dosing 55 efficacy tolerability 55 lintuzumab 55 rimonabant #mg 55 resynchronization therapy 55 HSCT 55 risedronate 55 NNRTI resistance 55 AVANDIA 54 neuropathological 54 antiangiogenic agents 54 CRLX# 54 efficacy 54 DAS# [002] 54 plasma concentrations 54 ADAGIO study 54 FOSRENOL ® 54 endothelial activation 54 Azedra 54 preoperative chemotherapy 54 lanthanum carbonate 54 darunavir ritonavir 54 glycemia 54 RECIST Response Evaluation Criteria 54 neoadjuvant 54 antihypertensive medications 54 Unified Parkinson Disease 54 SYNTAX trial 54 adalimumab Humira 54 inhaled iloprost 54 blood Phe levels 54 stratifying patients 54 LMWH 54 pharmacokinetics PK 54 insulin sensitizing 54 response CCyR 54 EDSS score 54 multicenter trials 54 custirsen 54 nonrandomized 54 moderate renal impairment 54 placebo controlled studies 54 zolmitriptan 54 tapentadol IR 54 hepatic fibrosis 54 TOP2A 54 CoFactor 54 PRECiSE 54 vertebral fracture 54 timepoint 54 ximelagatran 54 metabolic parameters 54 pitavastatin 54 serum phosphate levels 54 PSA nadir 54 TNF antagonist 54 plasma uric acid 54 ACUITY trial 54 disease modifying 54 antitumor effects 54 rTMS 54 Adalimumab 54 baseline HbA1c 54 pioglitazone 54 hsCRP 54 achieve statistical significance 54 LT NS# 54 anti arrhythmic 54 Secondary endpoints included 54 periprocedural MI 54 HbA1C 54 lesional 54 temsirolimus 54 carvedilol 54 pharmacodynamic profile 54 salmeterol fluticasone 54 interferon gamma 1b 54 Arikace 54 evaluable subjects 54 INC# 54 prostate cancer CRPC 54 relapsing multiple sclerosis 54 NIHSS score 54 weekly subcutaneous injections 54 dose escalation phase 54 plasma pharmacokinetics 54 timepoints 54 #mg dose [003] 54 valsartan 54 macroalbuminuria 54 ispinesib administered 54 attain statistical significance 54 ribavirin RBV 54 ICD therapy 54 iloprost 54 IGFBP 3 54 locoregional disease 54 HBeAg positive patients 54 DP b# 54 antiplatelet 54 enfuvirtide 54 cardiac resynchronization 54 pressor response 54 HAQ DI 54 CombAT 54 AGILECT R 54 aminotransferases 54 RRMS patients 54 antihypertensive agents 54 hemoglobin A1c HbA1c 54 VADT 54 intravenous immunoglobulin IVIg 54 Phase #b/#a trial 54 undetectable viral load 54 Secondary efficacy endpoints 54 mapatumumab 54 pentoxifylline 54 dose cytarabine 54 virologic suppression 54 dacarbazine chemotherapy 54 RLAI 54 annualized relapse 54 bicalutamide 54 posttransplant 54 SERMs 54 NIH CPSI 54 solifenacin 54 serum cortisol 54 undetectable HBV DNA 54 alicaforsen enema 54 atherothrombotic events 54 nonsignificant trend 54 subcutaneously administered 54 TNF alpha inhibitor 54 rALLy trial 54 unfractionated heparin 54 DACH platinum 54 SIMPADICO 54 abacavir lamivudine 54 IV bisphosphonates 54 IFN α 54 Personal CGM 54 heavily pretreated patients 54 alefacept 54 EFAPROXYN 54 subgroup analyzes 54 zoledronic acid 54 antiarrhythmic drug 54 FDG PET 54 virologic failure 54 relapsed ovarian cancer 54 antidiabetic drug 54 evaluable patients 54 INT# [002] 54 DAS# CRP 54 neratinib 54 DLTs 54 MoxDuo TM IR 54 mg/m2 dose 54 degarelix 54 FAMPYRA 54 dose statin therapy 54 RAPAFLO R 54 eltrombopag 54 eculizumab 54 CLBP 54 methotrexate MTX 54 neostigmine 54 intravenous bisphosphonates 54 pazopanib 54 APTIVUS 54 prospective randomized controlled 54 STRIDE PD 54 Zevalin consolidation 54 hyperphenylalaninemia HPA due 54 raltegravir 54 Alzheimer Disease Assessment 54 adjuvant therapies 54 GLYX 54 hematologic 54 comparator arm 54 cerebrovascular events 54 Plenaxis TM 54 EGFR TKI 54 μg dose 54 genotypic resistance 54 Focalin XR 54 RE LY trial 54 mg ustekinumab 54 pain palliation 54 Genz # 54 serum concentrations 54 QTc interval 54 serum BDNF 54 thrombolytic therapy 54 HGS ETR2 54 cilengitide 54 FOLFOX4 54 PD LID 54 cardioprotection 54 CTAP# Capsules 54 chemosensitivity 54 Lantus ® 54 antiplatelet drugs 54 xanthine oxidase inhibitor 54 pamidronate 54 CRp 54 ponatinib 54 PEGylated anti 54 telcagepant 54 AGHD 54 aPTT 54 non squamous histology 54 motesanib 54 BPH Symptom Score 54 rindopepimut 54 hypercalcemia 54 oral prodrug 54 Triolex 54 non selective NSAIDs 54 ganetespib 54 cardiovascular calcification 54 IL 1ß 54 intima media thickness 54 Plicera 54 ADHD RS 54 randomized controlled clinical trials 54 selegiline 54 anti TNF 54 ruxolitinib 54 predictive biomarker 54 Menerba 54 peginterferon alfa 2b 54 liposomal formulation 54 TMC# r 54 CaPre ™ 54 paliperidone palmitate 54 Gefitinib 54 serum IGF 54 tumor necrosis 53 trabedersen 53 vicriviroc 53 direct thrombin inhibitors 53 LHRH antagonists 53 vismodegib 53 RG# [001] 53 tarenflurbil 53 ranolazine 53 dasatinib Sprycel 53 Vidaza azacitidine 53 Octreolin 53 chronic periodontitis 53 IFN beta 53 hsCRP levels 53 limiting toxicity 53 cranial irradiation 53 K ras mutations 53 dosing interval 53 LDL C 53 Ceflatonin 53 cortical stimulation 53 SAPHRIS 53 Zerenex 53 liprotamase 53 serologically active SLE 53 Gabapentin GR 53 trastuzumab Herceptin ® 53 FOSRENOL R 53 neuroprotection 53 pharmacodynamic parameters 53 immunomodulatory agents 53 cardio protective 53 mitoxantrone 53 Ostarine 53 gefitinib Iressa 53 knee OA 53 molecular remissions 53 PEGPH# 53 clinical pharmacology studies 53 1mg dose 53 LEXIVA 53 alanine aminotransferase ALT 53 plus dexamethasone 53 alemtuzumab 53 crizotinib PF # 53 Pharmacokinetic studies 53 Natalizumab 53 dose cohorts 53 ALLHAT 53 parathyroidectomy 53 serum clusterin levels 53 mcg BID 53 dosing frequency 53 galiximab 53 ischemic cardiomyopathy 53 ixabepilone 53 cilostazol 53 DXA scan 53 efaproxiral 53 primary hypercholesterolemia 53 Bosentan 53 MIRAPEX 53 oxcarbazepine 53 ARCOXIA 53 Hedgehog inhibitor 53 ablative therapy 53 methotrexate therapy 53 PROTECT II 53 lipid lowering drugs 53 BH4 53 Index CDAI 53 HER2 expression 53 serum PSA 53 relapsed MM 53 Helicobacter pylori eradication 53 HDRS 53 noninferior 53 dopaminergic therapy 53 everolimus eluting stents 53 tiotropium bromide 53 colorectal liver metastases 53 Welchol 53 achieve sustained virologic 53 serologically active patients 53 ExTRACT TIMI 53 romiplostim 53 carboplatin paclitaxel 53 gemifloxacin 53 Vojo Vukovic MD Ph.D. 53 CYT# QbG# 53 plasma lipids 53 darunavir 53 plasma lipid 53 HIV HCV coinfected 53 probiotic supplementation 53 hypoglycemic events 53 virologic responses 53 laquinimod 53 clevidipine 53 HBeAg negative patients 53 rhTSH 53 CaPre TM 53 erythropoietic 53 endoscopic remission 53 PTHrP 53 T2DM 53 Mylotarg 53 nerve conduction velocity 53 androgen independent 53 phase IIb study 53 indacaterol 53 Imprime PGG 53 histologies 53 HbA 1c levels 53 FOLFOX6 53 Hsp# inhibition 53 Lupuzor ™ 53 coadministration 53 antihypertensive drugs 53 pharmacodynamic endpoints 53 metformin sulfonylurea 53 EGFR mutations 53 EXJADE 53 glycosylated hemoglobin levels 53 intact parathyroid hormone 53 citalopram 53 evaluating tivozanib 53 fenretinide 53 PRTX 53 adjuvant radiotherapy 53 Xanafide 53 eosinophilic asthma 53 Qnexa 53 fasting plasma glucose FPG 53 dobutamine 53 basal insulin 53 Zemiva 53 prodromal symptoms 53 levodopa therapy 53 PROactive study 53 preclinical efficacy 53 Kaplan Meier estimate 53 irbesartan 53 virologic breakthrough 53 CDK inhibitor 53 stratify patients 53 EDARBI 53 Traficet EN 53 CR nPR 53 samalizumab 53 platelet inhibitor 53 concomitant medications 53 pharmacologic treatments 53 elevated troponin 53 Diovan HCT 53 subclinical hypothyroidism 53 antidiabetic therapy 53 HPA axis suppression 53 ascending dose 53 serum calcium 53 placebo p 53 proliferative diabetic retinopathy 53 T1DM 53 beta blocker therapy 53 adjuvant chemotherapy 53 HMG CoA reductase inhibitors 53 systemic corticosteroid 53 tumor regression 53 QT QTc 53 rEEG 53 ISIS # 53 NV1FGF 53 STX# 53 endometrial hyperplasia 53 eszopiclone 53 busulfan 53 febuxostat 53 ritonavir boosted 53 florbetaben 53 dosing cohort 53 COR Analyzer 53 interferon alfa 53 leucovorin 53 statistically nonsignificant 53 glucose homeostasis 53 SVR# 53 RECIST criteria 53 Y BOCS 53 NYHA functional class 53 nonvertebral fracture 53 atazanavir ritonavir 53 TREDAPTIVE 53 ELND# 53 anastrozole 53 therapeutic regimens 53 beta 1a 53 NeuroStar TMS Therapy 53 SABCS 53 carotid plaque 53 subanalysis 53 carotid intima media 53 growth hormone secretion 53 biologic therapy 53 physiologic 53 neoadjuvant chemotherapy 53 MMSE score 53 remission CR 53 JAK inhibitors 53 alpha blocker 53 Victoza R 53 ZYBRESTAT 53 RAPTIVA 53 ACCORD Lipid 53 GRN# 53 Teriparatide 53 quetiapine 53 taxane therapy 53 inotropic 53 ADHD symptoms 53 nonvertebral fractures 53 gemcitabine carboplatin 53 Hematologic toxicity 53 fat oxidation 53 NNT = 53 micafungin 53 Cimzia TM 53 urocortin 2 53 nonfatal MI 53 chronic lymphocytic leukemia CLL 53 lasofoxifene 53 Dasatinib 53 antidepressant therapy 53 EBRT 53 biochemical recurrence 53 glitazones 53 IPX# 53 Pemetrexed 53 Vilazodone 53 maximally tolerated doses 53 sorafenib Nexavar 53 treprostinil 53 C1 INH 53 aromatase inhibitor 53 schizophrenia CIAS 53 eplerenone 53 VAPRISOL 53 KRAS status 53 DU #b 53 HAMD 53 HbA 1C 53 Telintra 53 JVRS 53 molindone 53 insulin sensitization 53 EXPAREL 53 tasocitinib 53 metastatic RCC 53 cardiac repolarization 53 Egrifta 53 postoperative AF 53 atherogenic lipids 53 mesalamine granules 53 diet pill Qnexa 53 Solid Tumors 53 intensive lipid lowering 53 mutated KRAS 53 inhaled nitric oxide 53 chronic neuropathic pain 53 O PPDS 53 A1C levels 53 olanzapine LAI 53 anti fibrotic 53 imatinib 53 statistical significance p